Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

EGFR-targeted antibody-drug conjugate

DRUG CLASS:

EGFR-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR amplification	Glioma	EGFR amplification	Glioma	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR positive	Squamous Cell Carcinoma of Head and Neck	EGFR positive	Squamous Cell Carcinoma of Head and Neck	becotatug vedotin Sensitive: C2 – Inclusion Criteria becotatug vedotin Sensitive : C2	becotatug vedotin Sensitive: C2 – Inclusion Criteria becotatug vedotin Sensitive : C2
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BL-B01D1 Sensitive: C2 – Inclusion Criteria BL-B01D1 Sensitive : C2	BL-B01D1 Sensitive: C2 – Inclusion Criteria BL-B01D1 Sensitive : C2
SOX2 overexpression	Triple Negative Breast Cancer	SOX2 overexpression	Triple Negative Breast Cancer	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3
CXCR4 overexpression	Triple Negative Breast Cancer	CXCR4 overexpression	Triple Negative Breast Cancer	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3	EGFR-targeted antibody-drug conjugate Resistant: C3 – Early Trials EGFR-targeted antibody-drug conjugate Resistant : C3
EGFR expression	Nasopharyngeal Carcinoma	EGFR expression	Nasopharyngeal Carcinoma	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3
EGFR positive	Nasopharyngeal Carcinoma	EGFR positive	Nasopharyngeal Carcinoma	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3
EGFR expression	Esophageal Cancer	EGFR expression	Esophageal Cancer	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3	becotatug vedotin Sensitive: C3 – Early Trials becotatug vedotin Sensitive : C3